Aqueous Release to Treat IOP Spikes Post-cataract Surgery
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03500809 |
|
Recruitment Status : Unknown
Verified July 2018 by Anant Sharma, Bedford Hospital NHS Trust.
Recruitment status was: Not yet recruiting
First Posted : April 18, 2018
Last Update Posted : July 27, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Intraocular pressure (IOP) rise after cataract surgery is an important and common problem. Over 300,000 cataract operations are done per year in the United Kingdom alone. IOP rise can adversely affect vision and can be particularly detrimental in glaucoma patients with pre-existing visual field defects. The aim of this study is to evaluate the efficacy and safety of aqueous humor release (also known as burping of the wound), a procedure that has been used for decades to quickly reduce acute IOP spikes following cataract surgery.
Currently there is no published evidence on a standard technique to perform wound burping. Similarly there is uncertainty around the amount and duration of the IOP decrease, and the type and frequency of complications eventually associated. This will be the first research project formally evaluating this procedure. This study will also help allay issues over fluid release in high IOPs and consequences of such dramatic IOP drop which concerns ophthalmologists who do not routinely use this technique.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Post-Op Complication Raised Ocular Pressure | Procedure: Aqueous release of the wound | Not Applicable |
At present there is no de facto standard to manage acute intraocular pressure (IOP) rise following cataract surgery. Several drugs, both topical and systemic, have been tested for their ability to blunt the acute IOP spike, nevertheless none has proven to be superior and consistently effective. Oral acetazolamide has demonstrated to help controlling IOP spikes following cataract surgery in glaucomatous eyes. However there are still constraints in its widespread use, as it may be contraindicated in patients with poor renal function, sickle cell disease and sulpha drug allergy.
As a result, many units including Moorfields Eye Hospital have used a technique called known as 'burping of the corneal wound' to release fluid from inside the anterior chamber of the eye. This makes logical sense as it reduces the pressure immediately and may remove some of the causes for raised IOP such as retained viscoelastic and inflammatory molecules from inside the eye. This technique has also been used to reduce IOP in patients already receiving pharmaceutical treatment.
The technique has been used for decades, however, there is no published evidence of a proposed technique, range of IOP decrease or frequency of complications. Thus, most surgeons in most units are cautious of 'burping the wound' as it may induce infection or other complications compromising the surgical outcome due to the sudden reduced IOP reduction. Nevertheless a similar approach, needle penetrating the eye to release aqueous and reduce IOP, is becoming more popular as the first approach to treat an acute angle closure crisis, where the presenting IOP is often very high, i.e. a much more difficult and dangerous situation than post cataract surgery.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 20 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Efficacy and Safety of Aqueous Humour Release (Burping) Performed at the Slit-lamp to Treat Acute Intraocular Pressure (IOP) Spikes Post-cataract Surgery |
| Estimated Study Start Date : | August 12, 2018 |
| Estimated Primary Completion Date : | January 12, 2019 |
| Estimated Study Completion Date : | July 12, 2019 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Aqueous release (Burping) of the wound
Following uneventful cataract surgery, wound "burping" will be performed in all eligible patients who gave their informed consent. The procedure will be offered whenever the intraocular pressure (IOP) is either higher than 30 mmHg or deemed inappropriate in view of the ocular condition (e.g. glaucoma). After 'burping' the wound, patients will have their IOP measured using Goldmann application tonometry (GAT) immediately and at 2 hours. The 'burping' procedure will be repeated until satisfactory pressure is achieved and care will be taken to avoid shallowing of the anterior chamber while fluid is released. We will assess for the presence of leaks from the wound with a Seidel test with fluorescein 5% once the IOP is satisfactory. To prevent any infection after each procedure, we will prescribe post-op drops including chloramphenicol 0.5% four times a day for 2 weeks or minimum of 3 days and these will continue as per routine. All other complications will be recorded at follow-up. |
Procedure: Aqueous release of the wound
Other Name: 'Burping' procedure |
- Efficacy of 'burping' the wound to reduce IOP (mmHg) post-cataract surgery when measured using Goldmann application tonometry (GAT) [ Time Frame: 6 months ]Reduction in IOP (mmHg) post-cataract surgery after the 'burping' procedure
- Range of IOP decrease (mmHg) [ Time Frame: 6 months ]To observe and record the range of IOP decrease (mmHg) from individual 'burping' procedures
- Frequency of complications post-'burping' procedure [ Time Frame: 6 months ]Observing the frequency of complications, including but not limited to, severe pain, worsening of vision, or infection
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 90 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patient whose post-operative IOP was regarded to be too high for visual safety, or higher than 30mmHg, on the same day or within 1 week of the surgery
Exclusion Criteria:
- Patients with IOP less than 30 mmHg or IOP deemed by clinician not too high to treat
- Patients unable to cooperate
- Patients who have undergone complicated cataract surgery
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03500809
| Contact: Anant Sharma, MBBS, FRCOphth | 01234355122 ext 01234 | anant.sharma@bedfordhospital.nhs.uk | |
| Contact: Rynda Nitiahpapand, MBBS | 01234355122 ext 01234 | rynda.nitiahpapand@bedfordhospital.nhs.uk |
| Principal Investigator: | Anant Sharma, MBBS, FRCOphth | Bedford Hospital Moorfields Eye Unit |
| Responsible Party: | Anant Sharma, Consultant Ophthalmic Surgeon, Bedford Hospital NHS Trust |
| ClinicalTrials.gov Identifier: | NCT03500809 |
| Other Study ID Numbers: |
IRAS 240539 |
| First Posted: | April 18, 2018 Key Record Dates |
| Last Update Posted: | July 27, 2018 |
| Last Verified: | July 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Cataract Postoperative Complications Lens Diseases Eye Diseases Pathologic Processes |

